Subscribe: Market Wire - Pharmaceuticals and Biotech: Biotech
http://img.marketwire.com/rss/mwPBBI.rss
Preview: Market Wire - Pharmaceuticals and Biotech: Biotech

Marketwired - Biotech



Marketwired - Biotech



Last Build Date: Fri, 30 Sep 2016 06:11:37 EDT

Copyright: Copyright: (C) Marketwired
 



Sernova Announces Appointment of New CFO

Fri, 30 Sep 2016 06:02:44 EDT

Pharma Veteran Scott Langille Brings Over 25 Years of Experience in Both Canada and the United States to Sernova




ANGLE PLC: Research Published in Clinical Chemistry

Fri, 30 Sep 2016 02:00:00 EDT

GUILDFORD, UNITED KINGDOM--(Marketwired - Sep 30, 2016) - ANGLE plc (AIM: AGL) (OTCQX: ANPCY)




Greater Des Moines Recognized as a Global Leader

Thu, 29 Sep 2016 17:27:59 EDT

Brookings Institution Report Identifies Greater Des Moines as a Metro That Is Redefining What It Means to Be a Global City




Doors Open to Technology Aims to Grow the Tech Talent Pool in B.C.

Thu, 29 Sep 2016 15:31:34 EDT

Inaugural Program Brings Together Local Tech Industry Including Microsoft, SAP, TELUS, ACL and More




Proove Biosciences Founder & CEO, Brian Meshkin, Set to Speak at Executive Next Practices Forum on Healthcare

Thu, 29 Sep 2016 14:09:39 EDT

Renowned Expert in the Field of Precision Medicine Joins Network of Fortune 500 C-Level Executives to Discuss Impact of Genomics on Improving Outcomes in Pain




Hamilton Thorne Extends the Term of Outstanding Debentures

Thu, 29 Sep 2016 13:51:56 EDT

BEVERLY, MA and TORONTO, ON--(Marketwired - Sep 29, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets announced today that is has reached an agreement to amend (the "Debenture Amendments") its $300,000 unsecured subordinated debentures (the "Debentures") dated August 29, 2012 to extend the maturity date of the Debentures from October 1, 2016 to October 1, 2017. All other terms and conditions of the Debentures, as amended, were ratified and confirmed.




EAG Laboratories Appoints Duane Huggett, Ph.D., as Senior Scientific Advisor for Its Environmental Testing Group

Thu, 29 Sep 2016 12:31:00 EDT

Expert in Environmental Risk Assessment, Toxicology and Pharmacology Joins Company




Governor Brown Signs Into Law the California Cancer Clinical Trials Program

Thu, 29 Sep 2016 11:00:00 EDT

New Law Will Help Increase Patient Enrollment, Retention, and Minority Participation in Cancer Clinical Trials, Especially Among Women and Under-Represented Communities




Amid 2016 Uptrend, Shares of Innovus Pharma Consolidate on Technical Support - SECFilings.com

Thu, 29 Sep 2016 10:04:29 EDT

REDONDO BEACH, CA--(Marketwired - Sep 29, 2016) -  SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article analyzing Innovus Pharmaceuticals' (OTCQB: INNV) stock chart from a technical perspective, along with a discussion of the company's fundamentals.




Clasado BioSciences to Showcase Bimuno(R) for First Time at SupplySide West

Thu, 29 Sep 2016 10:02:00 EDT

Leading Biotech Company Launches Patent Protected Galacto-Oligosaccharide Bimuno(R) (B-GOS(R)) at Prominent Industry Trade Show




vCom Awards Its Customers for Their Valuable Contributions in 2016

Thu, 29 Sep 2016 10:00:00 EDT

Technology Management Solutions Awards for Transformational Leaders




Endonovo at the Intersection of Stem Cells and Biologics for Next Generation Therapeutics - SECFilings.com

Thu, 29 Sep 2016 08:58:46 EDT

REDONDO BEACH, CA--(Marketwired - Sep 29, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public filing alerts, recently published an article covering the unique technology that Endonovo Therapeutics (OTCQB: ENDV) is applying in the development of biologics and stem cells.




Daxor Corporation Announces Two New Studies From the Mayo Clinic and Lankenau Medical Center Presented at Heart Failure Society of America 2016 Highlight Unique Ability of BVA to Identify High Risk at Discharge in Hospitalized Heart Failure Patients

Thu, 29 Sep 2016 08:30:00 EDT

NEW YORK, NY--(Marketwired - Sep 29, 2016) - Daxor Corporation (NYSE MKT: DXR), an investment company with medical instrumentation and biotechnology operations, announces two new studies presented at the Heart Failure Society of America meeting this month highlighting risks for hospitalized heart failure patients detectable by direct blood volume measurement (Daxor BVA-100).




iBio Proprietary Technology Advances Neonatal Respiratory Distress Syndrome Drug Development for South African Biotech Company AzarGen Biotechnologies (Pty) Ltd

Thu, 29 Sep 2016 08:30:00 EDT

NEW YORK, NY--(Marketwired - Sep 29, 2016) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products announced the successful application of its proprietary technologies to achieve the first milestone in its commercial development agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) of South Africa for the development and manufacture of an improved surfactant protein for the treatment of neonatal respiratory distress syndrome (RDS).




Critical Outcome Technologies Reports Fiscal 2017 First Quarter Financial and Operating Results

Thu, 29 Sep 2016 08:30:00 EDT

LONDON, ON and BOSTON, MA--(Marketwired - September 29, 2016) - Critical Outcome Technologies Inc. (TSX VENTURE: COT) (OTCQB: COTQF) ("COTI" or the "Company") reported its financial and operating results today for the three-month period ended July 31, 2016. Major highlights for the quarter included:




Thermo Fisher Opens Its Second Global IT Center of Excellence in Tijuana

Thu, 29 Sep 2016 08:00:00 EDT

TIJUANA, MEXICO and SAN DIEGO, CA--(Marketwired - September 29, 2016) - The establishment of Thermo Fisher's IT Tijuana-San Diego operations is a milestone for both cities' EDCs, and an example of how its complementary capabilities can make the CaliBaja region a leading global provider of IT services.




MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript

Thu, 29 Sep 2016 08:00:00 EDT

Peer-Reviewed Study Published in The Journal of the American College of Nutrition Demonstrating That Fortetropin(R) Increased Lean Body Mass (LBM), Increased Muscle Thickness, and Decreased Markers of Protein Breakdown




Aequus Obtains Ontario Provincial Listing for Vistitan(TM)

Thu, 29 Sep 2016 08:00:00 EDT

VANCOUVER, BC--(Marketwired - September 29, 2016) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has successfully obtained provincial formulary coverage from the Ontario Drug Benefit Program for PrVistitanT (bimatoprost 0.03% w/v, ophthalmic solution). According to IMS data, over 80% of Ontario's glaucoma patient population rely on public medication coverage, who will now have improved access to this product.




Cell MedX Corp. (CMXC) Cancels Options and Appoints a Director

Thu, 29 Sep 2016 08:00:00 EDT

LAS VEGAS, NEVADA--(Marketwired - Sept. 29, 2016) - Cell MedX Corp. (OTCQB:CMXC), ("Cell MedX" or the "Company") a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, is pleased to announce that on September 26, 2016 the Company cancelled options to acquire up to 17,500,000 common shares of the Company, at an initial price of $0.05 per share (the "Cancelled Options"). The Cancelled Options represent the unvested portion of those options that were initially granted to Ms. Arnett and Mr. Hargreaves on November 25, 2014.




Abeona Therapeutics to Present at Cell Gene Meeting on the Mesa

Thu, 29 Sep 2016 07:03:00 EDT

Company CEO to Present on October 5th at 11:15 am PT




RNA-Seq in Colorectal Cancer Defines Neoplastic and Stromal Features Impacting Future Treatments, New Webinar Hosted by Xtalks

Thu, 29 Sep 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - September 29, 2016) - In this webinar, industry expert Dr. Enzo Medico, Associate Professor at the University of Torino, School of Medicine, Candiolo Cancer Institute will outline research studies that have been performed to exploit global transcriptional profiling of colorectal cancer samples.




Vernalis PLC Announces Results Announcement for the 12 Months Ended 30 June 2016

Thu, 29 Sep 2016 02:00:00 EDT

WINNERSH, UNITED KINGDOM--(Marketwired - Sep 29, 2016) - Vernalis PLC (LSE: VER) (OTC PINK: VNLPY)




Tiziana Life Sciences PLC Announces Interim Results for the Six Months Ended 30 June 2016

Thu, 29 Sep 2016 02:00:00 EDT

LONDON, UNTIED KINGDOM--(Marketwired - Sep 29, 2016) - Tiziana Life Sciences plc (AIM: TILS)




Avita Medical Signs Exclusive Distributor Deal in Iran

Wed, 28 Sep 2016 23:42:19 EDT

Dedicated ReNovaCell(TM) Clinic to Open in Tehran




InspireMD Announces 1-for-25 Reverse Stock Split

Wed, 28 Sep 2016 16:01:00 EDT

BOSTON, MA--(Marketwired - Sep 28, 2016) - InspireMD, Inc. (NYSE MKT: NSPR) (NYSE MKT: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced a 1-for-25 reverse split of its common stock, effective as of October 7, 2016. Beginning on October 10, 2016, the Company's common stock will trade on the NYSE MKT on a split adjusted basis.




SMP Pharmacy Solutions Receives Eighth Inc. 5000 Recognition

Wed, 28 Sep 2016 15:07:37 EDT

Miami-Based Specialty Pharmacy Listed Among Top 20% of America's Fastest-Growing Private Companies




How Far Will You Go to Defeat Type 1 Diabetes

Wed, 28 Sep 2016 15:00:00 EDT

Canadians Ride Up to the Challenge; JDRF Revolution Ride




Medtronic, Phillips Healthcare Lead High Demand Billion Dollar U.S. Patient Monitoring Market

Wed, 28 Sep 2016 13:17:54 EDT

The U.S. Patient Monitoring Market Is Expected to Grow Over the Next Several Years to Reach Over $6 Billion by 2023




NCCN Congress to Explore Complex Issues in Treating Hematologic Malignancies

Wed, 28 Sep 2016 13:15:00 EDT

The NCCN 11th Annual Congress: Hematologic Malignancies(TM) Returns to New York City September 30 - October 1, 2016; Registration Is Still Open at NCCN.org/HEM




Commence Bio to Present at 2016 Cell & Gene Meeting on the Mesa

Wed, 28 Sep 2016 12:37:22 EDT

SPARKS, MD--(Marketwired - September 28, 2016) - Commence Bio, Inc., a biotechnology company focused on developing breakthrough immunotherapies using its proprietary STaRTT platform, announced today that Thomas Isett, CEO and Co-Founder, will present a company overview at the 2016 Cell & Gene Meeting on the Mesa [CGMOM]. Scheduled for October 5, at 2:45 PM (PDT), the presentation will highlight developments with the application of STaRT to create MSC1 and MSC2 cellular therapies for immuno-oncology and immune-mediated inflammatory diseases.




Clean Air Products Air Showers With New Touchscreen Interface Easily Control Cycle Time

Wed, 28 Sep 2016 12:00:00 EDT

Superior Air Flow Volume and Velocity, as Well as Durable Construction, Ensure Years of Efficient, Maintenance-Free Operation




Kane Biotech Announces Issuance of Common Shares in Payment of Outstanding Interest

Wed, 28 Sep 2016 11:02:14 EDT

WINNIPEG, MANITOBA--(Marketwired - Sept. 28, 2016) - Kane Biotech Inc. (TSX VENTURE:KNE) (the "Corporation") announced that on September 28, 2016, it issued 256,600 common shares of the Corporation ("Common Shares") in payment of $12,830 in interest owing on the Corporation's $500,000 2 year 10% convertible redeemable unsecured note (the "Note") as at September 18, 2016. Pursuant to the terms of the Note, the Corporation has the option to issue Common Shares in lieu of cash in payment of interest on the Note at a deemed price per share equal to the market price of the Common Shares on the applicable interest payment date, subject to a minimum price of $.05 per share and the approval of the TSX Venture Exchange (the "Exchange"). The approval of the Exchange for the issuance of the Common Shares was obtained by the Corporation on September 27, 2016. The Common Shares issued by the Corporation are restricted from transfer for a period of four months from the date of issuance in accordance with applicable securities laws and TSX Venture Exchange policies.




Neptune publiera ses résultats du deuxième trimestre pour la période intermédiaire terminée le 31 août 2016

Wed, 28 Sep 2016 10:51:09 EDT

LAVAL, QUÉBEC--(Marketwired - 28 sept. 2016) - Neptune Technologies & Bioressources inc. (NASDAQ:NEPT)(TSX:NTB) (« Neptune » ou « la Société »), annonce qu'elle tiendra une conférence téléphonique le 12 octobre 2016 à 17h00, (heure normale de l'est) afin de commenter les résultats financiers du deuxième trimestre pour la période intermédiaire terminée le 31 août 2016.




Neptune to Hold Conference Call to Discuss Second Quarter Results for the Period Ended August 31, 2016

Wed, 28 Sep 2016 10:50:32 EDT

LAVAL, QUÉBEC--(Marketwired - Sept. 28, 2016) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on October 12, 2016 at 5:00 PM (EST) to discuss its second quarter results for the period ended August 31, 2016.




Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients

Wed, 28 Sep 2016 10:40:45 EDT

IRVINE, CA--(Marketwired - Sep 28, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce Cannabis Science launches new medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. The new CBIS medicinal product lines are being released based on patient usage data and general public opinion. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize target medicines for target ailments. These new medicinal products will be centerpieces for its new medicinal studies targeting its initial critical ailment list.




Medrio Rocks the House Down With Live Software Demonstrations at SCDM 2016

Wed, 28 Sep 2016 10:00:00 EDT

SAN FRANCISCO, CA--(Marketwired - September 28, 2016) - Medrio, a Software as a Service (SaaS) company providing electronic data capture (EDC) services to clinical trials, brought its Medrio Rocks World Tour to the Society for Clinical Data Management (SCDM) conference in San Diego from September 11 - 13. Hundreds of clinical data management professionals filled the Sheraton San Diego Hotel & Marina, including over 200 Medrio fans, who rushed to the front row at booth 201 to rock out to the company's chart-topping EDC.




Theratechnologies va de l'avant avec le développement d'une nouvelle formulation en fiole unique d'EGRIFTA(MD) (tésamoréline pour injection)

Wed, 28 Sep 2016 09:56:08 EDT

MONTRÉAL, QUÉBEC--(Marketwired - 28 sept. 2016) - Theratechnologies inc. (Theratechnologies) (TSX:TH) a annoncé aujourd'hui qu'elle ira de l'avant avec le développement de la formulation F4 en une seule fiole. L'introduction d'une présentation à fiole unique faisait partie des engagements qui avaient été requis par la FDA au moment où elle a approuvé EGRIFTAMD. Theratechnologies a proposé que le développement de la formulation F4 soit poursuivi en remplacement du programme pour la présentation à 2mg/fiole ce que la FDA a permis de faire.




Theratechnologies to Move Forward With Development of New Single Vial Formulation for EGRIFTA(R) (Tesamorelin for Injection)

Wed, 28 Sep 2016 09:55:28 EDT

MONTREAL, QUEBEC--(Marketwired - Sept. 28, 2016) - Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that it will move forward with the development of the F4 single vial formulation instead of the 2mg/vial presentation. The introduction of a single vial presentation was part of commitments required by the FDA when it approved EGRIFTA®. Theratechnologies proposed that the development of the F4 single vial formulation be pursued in replacement of the current 2 mg/vial presentation, and the FDA allowed us to proceed as such.




New Features, Additional Keynote Speakers Will Round out 11th Annual Cardiometabolic Health Congress

Wed, 28 Sep 2016 09:39:41 EDT

BOSTON, MA--(Marketwired - September 28, 2016) - Continuing its dedication to translating late-breaking clinical research on cardiometabolic risk reduction into practical and targeted education, the Cardiometabolic Health Congress will hold its 11th Annual CMHC from October 5-8, 2016 at the Sheraton in Boston, MA.




Miryal(R): Organic Probiotic Soil Discovery Could Change Industry

Wed, 28 Sep 2016 09:30:00 EDT

Startling Discovery Means Living Product Can Remain Alive After Packaging for Two Years for Widespread Applications




AssistRx Shares Insight Into Maximizing Workflow Efficiency at the 7th Hub and SPP Model Optimization Conference

Wed, 28 Sep 2016 09:01:00 EDT

Company Calls on the Specialty Pharmaceutical Industry to Leverage Technology and Improve the Patient Experience




The Alliance for Regenerative Medicine Announces Fourth Annual 2016 European Advanced Therapies Investor Day

Wed, 28 Sep 2016 09:00:00 EDT

WASHINGTON, DC--(Marketwired - Sep 28, 2016) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, announced its annual European Advanced Therapies Investor Day will be held November 3, 2016 in London.




Defining Patient-Centricity Success Metrics & Demonstrating Initiative Value

Wed, 28 Sep 2016 08:31:00 EDT

20% of Pharmaceutical Companies Struggle Due to Increased Focus on Consumer Experience




GrowPros Announces Name Change to Tetra Bio-Pharma Inc., the Closing of A Non-Brokered Private Placement, and Extends Warrants

Wed, 28 Sep 2016 08:30:00 EDT

OTTAWA, ONTARIO--(Marketwired - Sept. 28, 2016) - GrowPros Cannabis Ventures Inc. ("GrowPros" or "the Company") (CSE:GCI) announces that the Company has changed its name to Tetra Bio-Pharma Inc. and has a new stock symbol CSE:TBP effective immediately.




Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility

Wed, 28 Sep 2016 08:05:00 EDT

EDMONTON, ALBERTA--(Marketwired - Sept. 28, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the grand opening of its new 30,000-square-foot bioprocessing extraction/manufacturing facility in Edmonton, Alberta, Canada.




Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation

Wed, 28 Sep 2016 07:30:00 EDT

Data Presented at the 6th European Workshop on Lipid Mediators, Wednesday, September 28 at 11:40 AM CET / 5:40 AM EST




mCig, Inc. CEO to Retire 50 Million Underlying Common Shares of Company Stock to the Company Treasury

Wed, 28 Sep 2016 07:00:00 EDT

HENDERSON, NV--(Marketwired - Sep 28, 2016) - mCig, Inc. (OTCQB: MCIG), a diversified company servicing the legal cannabis, hemp, and CBD markets, announced today its Chairman and CEO, Paul Rosenberg, is pleased to announce he has voluntarily returned 5 million Series A Preferred shares, representing 50 million underlying common stock to the company treasury. The process will be completed by September 30th, 2016.




Tissue Collection Standards Determine the Future of Precision Medicine, New Webinar Hosted by Xtalks

Wed, 28 Sep 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - September 28, 2016) - Join industry expert Dr. Hartmut Juhl, Professor, Founder and CEO of Indivumed GmbH and IndivuTest GmbH (Hamburg), as he discusses how tissue collections standards will play a role in the future of precision medicine. There will be two live broadcasts on Tuesday, October 18, 2016 at 9am EDT (2pm BST/UK) and 1pm EDT.




Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016

Wed, 28 Sep 2016 06:00:00 EDT

SAN FRANCISCO, CA--(Marketwired - September 28, 2016) - Medivation, Inc. (NASDAQ: MDVN) today announced that new data from Company-sponsored and investigator-initiated clinical trials will be presented at the European Society for Medical Oncology (ESMO) 2016 Congress, being held October 7-11, in Copenhagen. Presentations include a pilot study of the company's investigational PARP inhibitor talazoparib in patients with BRCA-mutated breast cancer, and analyses of enzalutamide in the advanced prostate cancer setting, representing research advances in serious diseases for which there are limited options.




Environmental Monitoring Boosting Global Microbiology Tech Market, Reports BCC Research

Wed, 28 Sep 2016 05:00:00 EDT

WELLESLEY, MA--(Marketwired - September 28, 2016) - Growth in environmental microbiology is moving the global market for microbiology technology, equipment, and consumables. BCC Research reveals in its new report that new technologies are facilitating simpler methods of handling samples, while the potential for biosensors is making this field less labor- and time-consuming, which is encouraging the expansion of microbiology technology applications for environmental monitoring.




Astavita Brings AstaMed(R) MYO, Prescription Medical Food for Clinical Dietary Management of Sarcopenia, Into Symplmed DyrctAxess Technology(R)

Tue, 27 Sep 2016 15:48:35 EDT

New Patient Membership Program to Improve Access to Medications for Individuals Living With Sarcopenia




Quidel Receives FDA Clearance for Its Solana(R) Influenza A+B Assay in Time for the Upcoming 2016-2017 Flu Season

Tue, 27 Sep 2016 13:14:18 EDT

SAN DIEGO, CA--(Marketwired - September 27, 2016) - Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its Solana® Influenza A+B assay for the detection of nucleic acids isolated from nasal and nasopharyngeal swabs from patients with signs and symptoms of respiratory infection to aid in the diagnosis of Influenza A and B infections. The Solana® Influenza A+B Assay is intended for use only with the Solana® instrument.




Genome BC Invests in Anandia Labs -- a Leader in Cannabis Biotechnology and Safety

Tue, 27 Sep 2016 12:00:00 EDT

VANCOUVER, BC--(Marketwired - September 27, 2016) - Genome BC is pleased to announce that it has made its first investment through its Industry Innovation (I²) Program to Anandia Laboratories Inc. (Anandia Labs). Anandia Labs is a Vancouver-based cannabis biotechnology company with two objectives: providing leading analytical testing services to the regulated cannabis industry in Canada; and developing improved cannabis and hemp strains for novel, safe, and effective medical applications. According to Health Canada, close to 70,000 Canadians patients are currently accessing medical marijuana from Canadian licensed producers.




Theratechnologies annoncera ses résultats du troisième trimestre de 2016

Tue, 27 Sep 2016 10:08:45 EDT

MONTRÉAL, QUÉBEC--(Marketwired - 27 sept. 2016) - Theratechnologies Inc. (TSX:TH) (Theratechnologies) a annoncé aujourd'hui qu'elle dévoilera ses résultats financiers du troisième trimestre de 2016 terminé le 31 août 2016, mardi le 4 octobre prochain, avant l'ouverture des marchés.

Une conférence téléphonique aura lieu à compter de 8 h 30 (heure de l'Est) la même journée, pour discuter des résultats. L'appel sera animé par Luc Tanguay, président et chef de la direction. Les analystes financiers seront invités à poser des questions lors de la conférence téléphonique. Les membres des médias et autres personnes intéressées sont invités à la conférence à titre d'auditeurs uniquement.




Theratechnologies to Announce Financial Results for the Third Quarter of 2016

Tue, 27 Sep 2016 10:08:00 EDT

MONTREAL, QUEBEC--(Marketwired - Sept. 27, 2016) - Theratechnologies Inc. (TSX:TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31, 2016, on Tuesday, October 4, 2016, before markets open.

A conference call will be held the same day at 8:30 a.m. (ET) to discuss the results. The call will be hosted by Luc Tanguay, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a "listen-only" basis.




Premier Biomedical Pain Management Solutions Announces Shipment of Initial Samples of Opioid-Free, 50-State Legal, CBD-Based Pain-Relieving Topical Patch

Tue, 27 Sep 2016 10:00:00 EDT

EL PASO, TX--(Marketwired - Sep 27, 2016) -  Premier Biomedical, Inc. (OTCQB: BIEI) announced today their newly created joint venture company, Premier Biomedical Pain Management Solutions, LLC (PBPMS) has manufactured and shipped initial design sample pain relieving topical patches for distribution to select VA hospital patients, military personnel, doctors, and professional sports figures. These patent-pending, opioid- and narcotic-free all-natural-ingredient topical pain relief patches consist of a proprietary mechanism for extended delivery of their cannabis-based medical CBD pain relieving compound, which is legal in all 50 states.




Prolacta Bioscience(R) Announces Formation of Scientific Advisory Board to Lead Further Breakthroughs in Advancing the Science of Human Milk(R)

Tue, 27 Sep 2016 10:00:00 EDT

Inaugural Board Convened During the 4th Annual International Conference on Human Milk Science and Innovation




AssistRx Announces Integration With Leading E-Prescribing Service, NewCrop

Tue, 27 Sep 2016 09:01:00 EDT

Market's Most Efficient Specialty Medication Workflow Solution Integrates With the E-Prescribing Service to Improve Capabilities for EHRs and Healthcare Organizations




Pega Launches Industry's First End-to-End Automation Platform to Intelligently Optimize How Work Gets Done With Robotic Automation, BPM, and CRM

Tue, 27 Sep 2016 09:00:00 EDT

Pega Robotic Automation Now Unified With Pega BPM Platform and CRM Applications to Automate Tasks, Streamline Processes, and Enhance Customer Engagement




Itonis, Inc. Announces Its Emesyl Anti-Nausea Product is Again Available for Purchase via Amazon.com

Tue, 27 Sep 2016 09:00:00 EDT

LAGUNA HILLS, CA--(Marketwired - September 27, 2016) - Itonis, Inc. (OTC PINK: ITNS) is pleased to announce that its Emesyl® anti-nausea homeopathic product is again available for purchase via Amazon.com.




Inaugural Techonomy Health Roundtable to Explore Healthcare in a Hyper-Connected Age

Tue, 27 Sep 2016 09:00:00 EDT

On November 9, Global Leaders Will Gather to Examine New Technologies, Attitudes and Opportunities Within the Connected Healthcare Ecosystem




The Alliance for Regenerative Medicine Submits Comments in Response to the European Commission's Draft Guidelines on Good Manufacturing Practice for Advanced Therapy Medicine Products

Tue, 27 Sep 2016 09:00:00 EDT

BRUSSELS, BELGIUM and WASHINGTON, DC--(Marketwired - Sep 27, 2016) - The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, has submitted written comments in response to the European Commission (EC)-issued targeted stakeholder consultation document on the draft Guidelines on Good Manufacturing Practice for Advanced Therapy Medicine Products (ATMP).




RepliCel Announces Debt Settlement

Tue, 27 Sep 2016 09:00:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 27, 2016) - RepliCel Life Sciences Inc. (OTCQB:REPCD)(TSX VENTURE:RP)(FRANKFURT:P6P2) ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce its intention to settle debt (the "Debt Settlement") in the aggregate amount of $374,071.63 owed by the Company to certain creditors by the issuance of 719,368 units (each, a "Unit"). Each Unit consists of one common share of the Company (each, a "Share") and one share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder to purchase one additional Share for a period of two years at a price of $1.10 per Share.




BioNap Consulting's Jason Napodano Issues an Update on BriaCell Therapeutics Corp.

Tue, 27 Sep 2016 08:30:00 EDT

BERKELEY, CA and VANCOUVER, BC--(Marketwired - September 27, 2016) - BioNap Consulting, Inc.'s Senior Equity Analyst, Jason Napodano, CFA, issued an update outlining the meaningful progress of BriaCell Therapeutics Corp. (TSX VENTURE: BCT) (OTCQB: BCTXF) or BriaCell towards initiation of Phase I/IIa clinical testing of BriaVaxT, BriaCell's proprietary allogeneic whole tumor cell vaccine, in late-stage breast cancer patients in the fourth quarter of 2016.




Breathtec Biomedical Engages DTG Partners to Advance Product Commercialization

Tue, 27 Sep 2016 08:30:00 EDT

Medical Product Development Consultancy Aims to Deliver Proven, Time-Efficient and Cost-Effective Expertise




North Springs Resources Corp. Announces the Unveiling of Major Business Announcement to Shareholders Before Oct 1st 2016

Tue, 27 Sep 2016 08:30:00 EDT

RIVERVIEW, FL--(Marketwired - Sep 27, 2016) - North Springs Resources Corp. (OTC PINK: NSRS) is pleased to announce that the Company has worked closely with the Company's strategic partner and plans to issue an update to shareholders on or before Oct 1st 2016 regarding a contractual agreement that is expected to have a substantial and beneficial impact on the Company and its shareholders.




Top 5 Factors Pharma Companies Consider When Compensating Clinical Investigators

Tue, 27 Sep 2016 08:19:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - September 27, 2016) - The most important factor to determining clinical investigator compensation is the physician's therapeutic specialty, according to a report published by pharmaceutical competitive intelligence firm Cutting Edge Information.




Plan Your Time at World Maker Faire New York, October 1 & 2, With These Valuable Resources

Tue, 27 Sep 2016 08:00:00 EDT

Public Transportation, Ride Share, & Biking Options Recommended




Reflect Scientific's Cryometrix Ultra Low Temperature Freezers Go International

Tue, 27 Sep 2016 08:00:00 EDT

OREM, UT--(Marketwired - September 27, 2016) - Reflect Scientific, Inc. (OTCQB: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical and transportation industries announced the first international order has been received from a major research institute in Bangkok, Thailand.

A prominent research institute in Bangkok, Thailand has placed an order for the Cryometrix T-90 ULT freezer for sample storage. In a correspondence sent to Reflect Scientific Inc. the institute wrote, "Currently, our organization has more than 100 units of -86C electrical freezers and our Director would like us to reduce electrical consumption and eliminate the use of CFC's. Your products were brought to our attention." The T-90 is a patented ultra low temperature freezer that utilizes liquid nitrogen as the coolant and uses very few moving parts resulting in a very environmentally friendly, reliable product. Mr. Boyce, CEO of Reflect Scientific Inc., commented, "I am excited to see that the excellent reputation of our Cryometrix freezers has spread to international customers. This opens up a large potential market for our freezer product line."




3D Signatures Inc. Appoints Jason Flowerday as New CEO

Tue, 27 Sep 2016 08:00:00 EDT

WINNIPEG, MB--(Marketwired - September 27, 2016) - 3D Signatures Inc. (TSX VENTURE: DXD) (the "Company" or "3D"), a novel personalized medicine company with a proprietary software platform based on the three-dimensional analysis of a patient's individual chromosomal arrangement -- or signature -- is pleased to announce they have appointed Jason Flowerday, B.Sc., MBA as the Company's new CEO.




La FDA accorde la désignation de médicament orphelin à SOR-C13 pour le cancer du pancréas

Tue, 27 Sep 2016 07:30:00 EDT

TORONTO, ONTARIO--(Marketwired - 27 sept. 2016) - Soricimed Biopharma Inc. (« Soricimed »), compagnie pharmaceutique spécialisée dans la recherche et la mise au point de thérapies contre le cancer à partir de peptides, est heureuse d'annoncer que la Food and Drug Administration (FDA) a accordé la désignation de médicament orphelin au peptide SOR-C13 pour le traitement du cancer du pancréas. Cette désignation vient donc après celle déjà accordée pour le cancer de l'ovaire.




Adgero Biopharmaceuticals to Present at the Fifth Annual OktoberINVESTfest, US - Bavaria, Germany Investors Conference in New York

Tue, 27 Sep 2016 07:30:00 EDT

German, US Business Leaders and Investors to Convene September 28th at NY Academy of Sciences




Soricimed's SOR-C13 Granted Orphan Drug Designation for Pancreatic Cancer by the U.S. FDA

Tue, 27 Sep 2016 07:30:00 EDT

TORONTO, ONTARIO--(Marketwired - Sept. 27, 2016) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing peptide-based cancer therapeutics, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to peptide SOR-C13 for the treatment of pancreatic cancer. This follows the same designation for ovarian cancer.




Ceapro Inc. Awarded 2016 BioAlberta Achievement Award for Company of the Year

Tue, 27 Sep 2016 07:05:00 EDT

EDMONTON, ALBERTA--(Marketwired - Sept. 27, 2016) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the Company has been awarded the 2016 BioAlberta Achievement Award for Company of the Year.




The LAM Foundation Hosts Largest Rare Lung Disease Conference of Its Kind in Cincinnati

Mon, 26 Sep 2016 20:29:52 EDT

New $3.6 Million NIH Grant for MILED Trial and New Clinical Guidelines for LAM Introduced at the Joint Meeting of Scientists and Patients




RepliCel Provides Update on Shiseido License and Co-Development for RCH-01

Mon, 26 Sep 2016 17:47:34 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 26, 2016) - RepliCel Life Sciences Inc. (OTCQB:REPCD)(TSX VENTURE:RP)(FRANKFURT:P6P2) ("RepliCel" or the "Company"), a clinical-stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update on the licensing and co-development of its RCH-01 product with Shiseido Company.




Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

Mon, 26 Sep 2016 17:15:00 EDT

Novel 4-1BB/HER2 Bispecific Demonstrates Differentiation Over Conventional 4-1BB mAb and HER2 mAb Approaches




VBI Vaccines Announces Results of Annual General and Special Meeting

Mon, 26 Sep 2016 16:30:00 EDT

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Sept. 26, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today announced the voting results from its annual general and special meeting (the "Meeting") held on September 23, 2016.




Biodel Announces 2016 Annual Meeting of Stockholders Set for October 24, 2016; Outlines Plan to Regain Compliance With Nasdaq Listing Requirements

Mon, 26 Sep 2016 16:30:00 EDT

DANBURY, CT--(Marketwired - September 26, 2016) - Biodel Inc. (NASDAQ: BIOD) today announced that its 2016 annual meeting of stockholders has been set for October 24, 2016. At that meeting, stockholders will vote on, among other things, matters necessary to complete Biodel's planned transaction with Albireo Limited pursuant to a previously announced share exchange agreement, including the issuance of shares of Biodel's common stock in the transaction and a proposed reverse stock split of Biodel's common stock at a ratio of 1-for-30 shares.




Ogilvy CommonHealth Worldwide's Ritesh Patel to Deliver a Keynote Address at the Technology for Marketing 2016 Conference

Mon, 26 Sep 2016 13:51:52 EDT

PARSIPPANY, NJ--(Marketwired - Sep 26, 2016) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP company (NASDAQ: WPPGY) (www.wpp.com), today announced Ritesh Patel, EVP, chief digital officer, has been selected as a keynote speaker at the 2016 Technology for Marketing event taking place on September 28 and 29 in Olympia London.




NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms

Mon, 26 Sep 2016 12:03:22 EDT

New NCCN Guidelines for Myeloproliferative Neoplasms Focus on the Treatment of Myelofibrosis, a Rare Bone Marrow Cancer; the New Recommendations Are the Most Comprehensive Treatment Guidance Available to U.S. Clinicians Today




MasterControl Provides Industry Insight on Leveraging Big Data in Post-Market Surveillance at Medical Product and Outsourcing's 2016 Summit

Mon, 26 Sep 2016 11:57:37 EDT

AUSTIN, TX--(Marketwired - Sep 26, 2016) -  MasterControl, a leading global provider of enterprise quality management systems (EQMS) and quality and compliance consulting services, will offer valuable information for the medical device industry at Medical Product and Outsourcing's Summit Oct. 5-6 in Austin, Texas.




Easton Pharmaceuticals Announces Receiving Mexican Regulatory Approval for VagiSan (VS-Sense) Diagnostic Device, in Support of On-Going Exclusive Distribution Negotiations With Multi-National Pharmaceutical Companies for Major Latin American Markets

Mon, 26 Sep 2016 10:45:42 EDT

TORONTO, ON--(Marketwired - Sep 26, 2016) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces COFEPRIS (Mexican Ministry of Health) has granted Marketing Authorization for VagiSan (also known as VS-Sense) diagnostic test, supporting on-going exclusive partnership negotiations for Mexico and other Latin American markets with several multinational pharmaceutical companies.




OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival

Mon, 26 Sep 2016 10:41:46 EDT

BATON ROUGE, LA--(Marketwired - September 26, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announces that OncBioMune Chief Executive Officer Dr. Jonathan Head will be making an abstract poster presentation today at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The conference is being hosted at the Sheraton New York Times Square Hotel in New York, New York from September 25-28.




tranSMART Foundation Announces Full Agenda for 2016 Annual Conference

Mon, 26 Sep 2016 10:35:53 EDT

Six Keynote and 42 Session Speakers to Discuss Varying Aspects of Translational Medicine From Data Harmonization and Open Data and Intellectual Property to Scalable Genomics




Mr. Raymond C. Dabney, CBIS CEO, Accepts Invitation to Speak at Harvard Medical School

Mon, 26 Sep 2016 10:18:41 EDT

WASHINGTON, DC--(Marketwired - Sep 26, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, announces that its President, Chief Executive Officer, and Co-Founder, Mr. Raymond C. Dabney, has accepted an invitation to speak at Harvard Medical School this November. Mr. Dabney will speak at the Dana Farber/Harvard Cancer Center (DF/HCC), one of the largest cancer research centers in the world with more than 1,100 cancer researchers and over $600 million in cancer research funding. He will discuss CBIS' drug development initiatives targeting a variety of cancers, within the context of a number of other disorders, such as autism spectrum disorders, asthma, as well as pain management.




Sermonix Pharmaceuticals' Exploratory Analysis on Orgasm Frequency With SERMs Is Named Featured Poster for 2016 North American Menopause Society Annual Meeting

Mon, 26 Sep 2016 09:55:00 EDT

Sermonix Also to Present Poster on Physicians' Perceptions of SERMs in Menopausal Health




TraceLink to Discuss Global Serialisation Strategies at CPhI Worldwide

Mon, 26 Sep 2016 09:00:00 EDT

NORTH READING, MA--(Marketwired - Sep 26, 2016) -  TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, will be addressing delegates at CPhI Worldwide, the annual pharmaceutical congress taking place October 4 - 6, in Barcelona, Spain. TraceLink will be partnering with its customer, Sharp Packaging Services, to display its proven Life Sciences Cloud solution in the Sharp CPhI booth in Hall 3, Stand L56.




Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day

Mon, 26 Sep 2016 08:30:00 EDT

LEXINGTON, MA--(Marketwired - Sep 26, 2016) - Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)




VBI Vaccines to Present at the Ladenburg Thalmann Healthcare Conference

Mon, 26 Sep 2016 08:30:00 EDT

CAMBRIDGE, MASSACHUSETTS--(Marketwired - Sept. 26, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 27, 2016 at 10:00 AM ET. The event is being held at the Sofitel New York Hotel in New York, NY.




Pacific Therapeutics Receives Revenue Update from Tower Three

Mon, 26 Sep 2016 08:30:00 EDT

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 26, 2016) - Pacific Therapeutics Ltd. (CSE:PT)(OTC PINK:PCFTF)(Frankfurt:1P3) (the "Company") announces that it has received a corporate update regarding its proposed transaction (the "Transaction") with Tower Three SAS (the "T3"), a South American telecommunications infrastructure developer. T3 has received its first rental payment from a major telecom provider (the "Anchor Tenant") for use of three towers out of the first ten tower development. The Company has received information that T3's fourth and fifth towers are expected to be completed and connected within the next several weeks. In addition, the remaining five towers are in the late stages of social development consultation. The Company was also informed that T3 has been awarded ten additional search rings (Desired Coordinates) from a cellular carrier, for areas in which cellular coverage and capacity is weak or lacking. Alex Ochoa CEO of T3, states: "This is a monumental milestone for Tower Three as we have now become a reoccurring revenue generating company with immediate cash returns starting within 45 days of every tower construction completion."




PhytoPain Pharma Provides USA Regulatory Update for Its Cannabis Inhalation Product PPP001

Mon, 26 Sep 2016 08:30:00 EDT

OTTAWA, ONTARIO--(Marketwired - Sept. 26, 2016) - PhytoPain Pharma ("PPP"), a subsidiary of GrowPros Cannabis Ventures Inc. ("GrowPros" or the "Company" or "GCI") (CSE:GCI), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions, received an Acknowledgement Letter from the U.S. Food and Drug Administration ("FDA") after submitting a Request for Designation ("RFD"). PPP had filed a RFD for PPP001 to be classified as a drug and assigned to the Center for Drug Evaluation and Research ("CDER"). The RFD enables the FDA to determine the product type and appropriate lead center. If the FDA has not issued a designation letter within 60 calendar days of the filing of the RFD, PPP's recommendation will become the designated classification and assignment.




DiamiR Provides Update on Its Patent Portfolio, Launches New Website

Mon, 26 Sep 2016 08:02:00 EDT

MONMOUTH JUNCTION, NJ--(Marketwired - September 26, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, reported today that the following new patents have been issued or allowed between April and September 2016:

"Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases" in Europe (issued in the United States in February 2014);




ORYZON Closes EUR 5.3 Million (6 M USD) in additional Debt Financing

Mon, 26 Sep 2016 08:00:00 EDT

With These Funds the Company Completes Its Global Funding of EUR 32 Million (36 Million USD)




DiaMedica to Present at the 16th Annual Biotech in Europe Forum for Global Partnering and Investment Conference

Mon, 26 Sep 2016 08:00:00 EDT

MINNEAPOLIS, MINNESOTA--(Marketwired - Sept. 26, 2016) - DiaMedica Inc. (the "Company") (TSX VENTURE:DMA)(OTCQB:DMCAF), a biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will present at the 16th Annual Biotech in Europe Forum for Global Partnering and Investment Conference being held September 27-28, 2016 at the Congress Center, Basel, Switzerland. Mr. Rick Pauls, President and CEO of DiaMedica, will present on Tuesday September 27, 2016 at 9:30am CET.




Beleave Provides Business Update

Mon, 26 Sep 2016 07:30:00 EDT

TORONTO, ON--(Marketwired - September 26, 2016) - Beleave Inc. ("Beleave" or the "Company") (CSE: BE) is pleased to announce that it has received notification from Health Canada that, upon the Company's confirmation that the Company's proposed site and storage security measures are in place, functional and comply with the requirements of the Access to Cannabis for Medical Purposes Regulations (the "ACMPR") and the Security Directive, Health Canada will prepare to request a pre-licensing inspection of the Company's proposed site. The issuance of a license under the ACMPR is in part dependent upon the completion of a satisfactory pre-licensing inspection by Health Canada of the Company's proposed site.




Abeona Therapeutics Enrolls First Patient in Phase 2 for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa

Mon, 26 Sep 2016 07:03:00 EDT

NEW YORK, NY and CLEVELAND, OH--(Marketwired - September 26, 2016) - Abeona Therapeutics Inc. (NASDAQ: ABEO)

  • Phase 1 clinical trial in five patients demonstrated EB-101 (gene corrected skin grafts) was well tolerated and demonstrated promising clinical efficacy in patients for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)
  • Significant improvements in wound healing and gene expression observed up to 12 months post-treatment

Abeona Therapeutics Inc. (NASDAQ: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene therapies for life-threatening rare diseases, announced that the first patient was enrolled in the Phase 2 portion of the clinical trial for EB-101 (gene-corrected skin grafts). EB-101 is the Company's lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of epidermolysis bullosa (EB).




Upcoming Webinar to Examine Market Access Hurdles for Cell and Gene Therapies

Mon, 26 Sep 2016 07:00:00 EDT

TORONTO, ON--(Marketwired - September 26, 2016) - The presentation will focus on managing evidence including market access and reimbursement challenges around cell and gene therapies to enhance market adoption.




If Canada Adopts New Zealand's Prescription Drug Policies There Will Be Fewer Treatment Options and Poorer Health Outcomes for Patients: Canadian Health Policy Institute (CHPI) Study

Mon, 26 Sep 2016 06:00:00 EDT

TORONTO, ON--(Marketwired - September 26, 2016) - The federal House of Commons Standing Committee on Health has been holding ongoing hearings about the Development of a National Pharmacare Program in Canada. Advocates of national pharmacare have told the Committee that Canada should adopt a New Zealand-style prescription drug system. However, a new study suggests that importing New Zealand-styled pharmacare policies into our country would lead to fewer drug treatment options and poorer health outcomes for Canadian patients.




Insight Pharma Reports' Gene Therapy Market Report: Moving Toward Commercialization

Fri, 23 Sep 2016 13:00:00 EDT

Focusing on Clinical-Stage Gene Therapy Programs Aimed at Commercialization